---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-223292"
form_type: "8-K"
ticker: "SEPN"
cik: "0001984086"
company_name: "Septerna, Inc."
filed_at: "2025-09-29T23:59:59+00:00"
generated_at: "2026-05-17T05:27:48.621122+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Septerna appoints Keith Gottesdiener, M.D. to board as Class I director and R&D Committee chair

## Summary
- Appointment effective Sept 25; board expanded to eight; Gottesdiener serves three-year term until 2028.
- Also appointed to Compensation Committee and as chair of newly constituted R&D Committee effective Sept 26.
- Gottesdiener is independent under Nasdaq/SEC rules; no material transactions or family relationships with officers.
- Compensation per standard non-employee director policy plus $12,000 annual retainer for R&D Committee chair.
- Former CEO of Prime Medicine and Rhythm Pharmaceuticals; 16 years at Merck with over 20 drug approvals.

## SEC filing metadata
- accession: 0001193125-25-223292
- form_type: 8-K
- ticker: SEPN
- cik: 0001984086
- company_name: Septerna, Inc.
- filed_at: 2025-09-29T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1984086/000119312525223292/0001193125-25-223292-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1984086/000119312525223292/d942032d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-223292
- JSON: https://secwatch.observer/filing/0001193125-25-223292.json
- Plain text: https://secwatch.observer/filing/0001193125-25-223292.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.